Want to see COYA full AI Analyst Report?
Top Page
Coya Therapeutics, Inc.
(NASDAQ:COYA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.00
▼(-5.88% Downside)
Action:Reiterated
Date:07/14/26
The score is held down primarily by weak financial performance (large ongoing losses and continued cash burn). Technicals are neutral with no strong trend, valuation is constrained by negative earnings and no dividend, while corporate events provide a modest positive offset through regulatory progress and recent financing.
Positive Factors
Regulatory progress for COYA 302
Fast Track designation and IND acceptance materially reduce regulatory friction and can accelerate clinical interactions. For a development‑stage biotech, these designations lower execution risk, improve investor/partner visibility, and increase the odds of timely enrollment and near‑term data catalysts over the next 2–6 months.
Negative Factors
Ongoing operating cash burn
Persistent negative operating and free cash flows indicate the business is not self‑funding. Continued cash burn forces reliance on external capital to complete Phase 2 programs, creating execution and runway risk and potentially constraining investment in parallel programs over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress for COYA 302
Fast Track designation and IND acceptance materially reduce regulatory friction and can accelerate clinical interactions. For a development‑stage biotech, these designations lower execution risk, improve investor/partner visibility, and increase the odds of timely enrollment and near‑term data catalysts over the next 2–6 months.
Read all positive factors
Coya Therapeutics, Inc. (COYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$98.29M
Dividend YieldN/A
Average Volume (3M)266.35K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth115.44%
EPS Growth-1.14%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.25Price Target Upside258.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.36
Revenue Forecast (FY)$2.37M
Coya Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biolo...
How the Company Makes Money
COYA is a clinical-stage biotechnology company and, based on publicly available information, does not primarily rely on product sales from approved therapies to generate revenue. Instead, the company’s revenue model is generally tied to (i) collab...
Coya Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.94M | 7.95M | 3.55M | 6.00M | 0.00 | 0.00 |
| Gross Profit | 7.92M | 7.92M | -8.31M | 500.68K | -4.41M | 0.00 |
| EBITDA | -21.10M | -21.20M | -17.20M | -7.33M | -9.26M | -4.88M |
| Net Income | -21.13M | -21.23M | -14.88M | -7.99M | -12.24M | -4.89M |
Balance Sheet | ||||||
| Total Assets | 53.27M | 49.95M | 44.35M | 41.26M | 8.40M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 50.72M | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 12.97M | 0.00 |
| Total Liabilities | 4.30M | 6.92M | 4.77M | 5.63M | 16.79M | 1.15M |
| Stockholders Equity | 48.97M | 43.03M | 39.58M | 35.64M | -8.39M | 3.64M |
Cash Flow | ||||||
| Free Cash Flow | -14.12M | -10.74M | -10.29M | -11.19M | -7.24M | -4.04M |
| Operating Cash Flow | -14.12M | -10.74M | -10.29M | -11.19M | -7.24M | -3.90M |
| Investing Cash Flow | -2.05M | -1.16M | -25.00K | -543.19K | -525.00K | -136.80K |
| Financing Cash Flow | 31.36M | 20.39M | 16.03M | 38.43M | 9.36M | -340.58K |
Coya Therapeutics, Inc. Technical Analysis
Negative
4.25
Price Trends
4.85
Negative
4.60
Negative
5.02
Negative
Market Momentum
-0.18
Negative
48.61
Neutral
85.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Negative. The current price of 4.25 is below the 20-day moving average (MA) of 4.51, below the 50-day MA of 4.85, and below the 200-day MA of 5.02, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 48.61 is Neutral, neither overbought nor oversold. The STOCH value of 85.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COYA.
Coya Therapeutics, Inc. Risk Analysis
Coya Therapeutics, Inc. disclosed 80 risk factors in its most recent earnings report. Coya Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Coya Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $67.74M | 4.34 | 35.58% | ― | 93.50% | ― | |
53 Neutral | $638.93M | -11.22 | -60.73% | ― | -78.29% | 54.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $98.29M | -3.64 | -57.26% | ― | 115.44% | -1.14% | |
46 Neutral | $74.45M | -1.02 | -318.08% | ― | ― | 20.55% | |
45 Neutral | $149.53M | -1.56 | -30.90% | ― | ― | 10.70% | |
42 Neutral | $55.70M | -0.40 | -666.47% | ― | -100.00% | 46.40% |
* Healthcare Sector Average
COYA
Coya Therapeutics, Inc.
4.58
-1.52
-24.92%
INO
Inovio Pharmaceuticals
0.67
-0.77
-53.26%
SPRO
Spero Therapeutics
1.27
-0.90
-41.47%
ANVS
Annovis Bio
1.86
-0.74
-28.46%
NKTX
Nkarta
2.29
0.28
13.93%
STTK
Shattuck Labs
7.16
6.38
817.95%
Coya Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Coya Therapeutics Shareholders Back Board, Auditor at Meeting
Positive
Jun 25, 2026
On June 25, 2026, Coya Therapeutics, Inc. held its Annual Meeting of Stockholders, where shareholders voted on the election of two Class I directors and the ratification of the company’s independent auditor for the 2026 fiscal year. Former U...
Business Operations and StrategyPrivate Placements and Financing
Coya Therapeutics Establishes $30 Million ATM Equity Program
Neutral
May 12, 2026
On May 12, 2026, Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC that allows the company to offer and sell up to $30 million of its common stock through at-the-market offerings on the Nasdaq Capital Market. The sha...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
Positive
May 12, 2026
On May 12, 2026, Coya Therapeutics reported first-quarter 2026 results and a corporate update, highlighting U.S. FDA Fast Track Designation granted on March 11, 2026 for its ALS candidate COYA 302 and FDA acceptance of an IND for COYA 302 in front...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.